BioVisioN AG Receives United States Patent For Peptide-Biomarker Discovery And Identification Technology
10/19/2005 5:13:14 PM
HANOVER, Germany--(BUSINESS WIRE)--April 7, 2005--The patent office of the United States of America has granted the patent for BioVisioN's core technology, the "Differential Peptide Display(R)" (DPD), for the discovery and identification of peptide biomarkers. The methods of this German biotech company allow the analysis and comparison of peptides in any biological sample and represent the most important component of the company's Peptidomics(R) technologies. Peptides are being valued and intensely researched by the pharmaceutical industry because of their potential as biomarkers and drugs. BioVisioN has already received patents for the DPD-Technology in Europe and other important pharmaceutical markets.
Using mass spectrometry BioVisioN's Differential Peptide Display analyses virtual every peptide in clinical samples like blood or urine, offering sensitivities down to picograms per milliliter. Using bioinformatic software tools developed in-house, the quantitative comparison of hundreds of samples is possible, making the technology suitable for biomarker discovery within clinical trials. The comparison of samples from e.g. patients and healthy controls shows up quantitative differences in peptide content characteristic of the disease studied. This provides for the identification of new diagnostic markers or biomarkers and also therapeutic leads and targets.
comments powered by